Search Results - "Roberts, Mark S"

Refine Results
  1. 1

    Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016 by Jalal, Hawre, Buchanich, Jeanine M, Roberts, Mark S, Balmert, Lauren C, Zhang, Kun, Burke, Donald S

    “…Better understanding of the dynamics of the current U.S. overdose epidemic may aid in the development of more effective prevention and control strategies. We…”
    Get full text
    Journal Article
  2. 2

    Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals by Chhatwal, Jagpreet, Wang, Xiaojie, Ayer, Turgay, Kabiri, Mina, Chung, Raymond T., Hur, Chin, Donohue, Julie M., Roberts, Mark S., Kanwal, Fasiha

    Published in Hepatology (Baltimore, Md.) (01-11-2016)
    “…Oral direct‐acting antivirals (DAAs) represent a major advance in hepatitis C virus (HCV) treatment. Along with recent updates in HCV screening policy and…”
    Get full text
    Journal Article
  3. 3

    The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions by KABIRI, Mina, JAZWINSKI, Alison B, ROBERTS, Mark S, SCHAEFER, Andrew J, CHHATWAL, Jagpreet

    Published in Annals of internal medicine (05-08-2014)
    “…Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting…”
    Get full text
    Journal Article
  4. 4

    Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women by NAYAK, Smita, ROBERTS, Mark S, GREENSPAN, Susan L

    Published in Annals of internal medicine (06-12-2011)
    “…The best strategies to screen postmenopausal women for osteoporosis are not clear. To identify the cost-effectiveness of various screening strategies…”
    Get full text
    Journal Article
  5. 5

    What Does the Value of Modern Medicine Say about the $50,000 per Quality-Adjusted Life-Year Decision Rule? by Braithwaite, R. Scott, Meltzer, David O., King, Joseph T., Leslie, Douglas, Roberts, Mark S.

    Published in Medical care (01-04-2008)
    “…Background: In the United States, $50,000 per Quality-Adjusted Life-Year (QALY) is a decision rule that is often used to guide interpretation of…”
    Get full text
    Journal Article
  6. 6

    Modeling the Impact of COVID-19 Mitigation Strategies in Pennsylvania, USA by Krauland, Mary G., Roberts, Mark S.

    Published in MDM policy & practice (01-01-2024)
    “…Purpose. To estimate the impact on mortality of nonpharmaceutical interventions (NPIs) implemented early in the COVID-19 pandemic. Methods. We implemented an…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Anxiety, Fear of Cancer, and Perceived Risk of Cancer following Lung Cancer Screening by Byrne, Margaret M., Weissfeld, Joel, Roberts, Mark S.

    Published in Medical decision making (01-11-2008)
    “…Background. Lung cancer screening can result in a high rate of indeterminate findings and has not yet been proven to be efficacious in reducing mortality. To…”
    Get full text
    Journal Article
  9. 9

    Survival after liver transplantation in the United States: A disease‐specific analysis of the UNOS database by Roberts, Mark S., Angus, Derek C., Bryce, Cindy L., Valenta, Zdenek, Weissfeld, Lisa

    Published in Liver transplantation (01-07-2004)
    “…Our goal was to describe disease‐specific survival and the clinical variables that predict survival in a large national cohort of adult liver transplant…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Using time-varying models to estimate post-transplant survival in pediatric liver transplant recipients by Bryce, Cindy L, Chang, Chung Chou H, Ren, Yi, Yabes, Jonathan, Zenarosa, Gabriel, Iyer, Aditya, Tomko, Heather, Squires, Robert H, Roberts, Mark S

    Published in PloS one (31-05-2018)
    “…To distinguish clinical factors that have time-varying (as opposed to constant) impact upon patient and graft survival among pediatric liver transplant…”
    Get full text
    Journal Article
  12. 12

    Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States by Chhatwal, Jagpreet, Kanwal, Fasiha, Roberts, Mark S, Dunn, Michael A

    Published in Annals of internal medicine (17-03-2015)
    “…Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Can a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study by Williams, Katherine V, Krauland, Mary G, Harrison, Lee H, Williams, John V, Roberts, Mark S, Zimmerman, Richard K

    Published in Vaccines (Basel) (26-10-2022)
    “…Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine…”
    Get full text
    Journal Article
  15. 15

    Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden by Krauland, Mary G., Zimmerman, Richard K., Williams, Katherine V., Raviotta, Jonathan M., Harrison, Lee H., Williams, John V., Roberts, Mark S.

    Published in Vaccine: X (01-04-2023)
    “…•We used an agent-based model to estimate the impact of more effective influenza vaccines.•Simulations included vaccine effectiveness ranging from 40 to…”
    Get full text
    Journal Article
  16. 16

    Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation by King, Joseph T., Tsevat, Joel, Lave, Judith R., Roberts, Mark S.

    Published in Medical decision making (01-11-2005)
    “…Background . Health-state preferences can be combined with willingness-to-pay (WTP) data to calculate WTP per quality-adjusted life year (QALY). The WTP/QALY…”
    Get full text
    Journal Article
  17. 17

    Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment by Nayak, Smita, Roberts, Mark S, Greenspan, Susan L

    Published in PloS one (13-03-2012)
    “…Since alendronate became available in generic form in the Unites States in 2008, its price has been decreasing. The objective of this study was to investigate…”
    Get full text
    Journal Article
  18. 18

    Development of a Synthetic Population Model for Assessing Excess Risk for Cardiovascular Disease Death by Krauland, Mary G, Frankeny, Robert J, Lewis, Josh, Brink, LuAnn, Hulsey, Eric G, Roberts, Mark S, Hacker, Karen A

    Published in JAMA network open (01-09-2020)
    “…Evaluating the association of social determinants of health with chronic diseases at the population level requires access to individual-level factors…”
    Get full text
    Journal Article
  19. 19

    Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism by Aujesky, Drahomir, Smith, Kenneth J, Cornuz, Jacques, Roberts, Mark S

    Published in Chest (01-09-2005)
    “…Low-molecular-weight heparin (LMWH) appears to be safe and effective for treating pulmonary embolism (PE), but its cost-effectiveness has not been assessed. We…”
    Get more information
    Journal Article
  20. 20

    Evaluating the effectiveness of problem-solving courts at preventing fatal and non-fatal opioid events: preliminary findings from Indiana by Van Nostrand, Elizabeth, Johnston, Alyssa, Albert, Steven M, Brown, Andre L, Buchanich, Jeanine M, Ray, Brad, Roberts, Mark S

    Published in Drugs in Context (2021)
    “…Fatal and non-fatal events associated with drug misuse are skyrocketing in most United States jurisdictions, including Indiana. Historically, the role of the…”
    Get full text
    Journal Article